To conclude, multiomics analysis revealed that CCNA2 is a potential biomarker for the diagnosis, treatment, and prognosis of CRC and is associated with immune infiltration, TF, and miRNA. This evidence concerns the gene CCNA2 and colorectal carcinoma.